SG10201403751XA - Fgf-r4 receptor-specific antagonists - Google Patents

Fgf-r4 receptor-specific antagonists

Info

Publication number
SG10201403751XA
SG10201403751XA SG10201403751XA SG10201403751XA SG10201403751XA SG 10201403751X A SG10201403751X A SG 10201403751XA SG 10201403751X A SG10201403751X A SG 10201403751XA SG 10201403751X A SG10201403751X A SG 10201403751XA SG 10201403751X A SG10201403751X A SG 10201403751XA
Authority
SG
Singapore
Prior art keywords
fgf
receptor
specific antagonists
antagonists
specific
Prior art date
Application number
SG10201403751XA
Inventor
Nicolas Baurin
Pierre-François Berne
Francis Blanche
Françoise Bono
Béatrice Cameron
Tarik Dabdoubi
Corentin Herbert
Vincent Mikol
Elisabeth Remy
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201403751X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of SG10201403751XA publication Critical patent/SG10201403751XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201403751XA 2008-07-08 2009-07-07 Fgf-r4 receptor-specific antagonists SG10201403751XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803888A FR2933702A1 (en) 2008-07-08 2008-07-08 SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR

Publications (1)

Publication Number Publication Date
SG10201403751XA true SG10201403751XA (en) 2014-09-26

Family

ID=40626849

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201403751XA SG10201403751XA (en) 2008-07-08 2009-07-07 Fgf-r4 receptor-specific antagonists

Country Status (38)

Country Link
US (1) US20110150903A1 (en)
EP (1) EP2315781B1 (en)
JP (2) JP5726731B2 (en)
KR (1) KR20110028536A (en)
CN (2) CN102149730B (en)
AR (1) AR072699A1 (en)
AU (1) AU2009267834B2 (en)
BR (1) BRPI0915660A2 (en)
CA (1) CA2730300A1 (en)
CL (1) CL2011000047A1 (en)
CO (1) CO6440535A2 (en)
CR (1) CR11868A (en)
CY (1) CY1116847T1 (en)
DK (1) DK2315781T3 (en)
DO (1) DOP2011000005A (en)
EA (2) EA021580B1 (en)
EC (1) ECSP11010748A (en)
ES (1) ES2544761T3 (en)
FR (1) FR2933702A1 (en)
HK (1) HK1159133A1 (en)
HN (1) HN2011000074A (en)
HR (1) HRP20150836T1 (en)
HU (1) HUE027221T2 (en)
IL (1) IL210516A0 (en)
MA (1) MA32547B1 (en)
MX (1) MX2011000328A (en)
NI (1) NI201100012A (en)
NZ (2) NZ590860A (en)
PE (1) PE20110313A1 (en)
PL (1) PL2315781T3 (en)
PT (1) PT2315781E (en)
SG (1) SG10201403751XA (en)
SI (1) SI2315781T1 (en)
TW (1) TW201006492A (en)
UA (1) UA107782C2 (en)
UY (1) UY31970A (en)
WO (1) WO2010004204A2 (en)
ZA (1) ZA201100209B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139985A1 (en) * 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2812389C (en) * 2010-09-27 2019-12-31 John Kehoe Antibodies binding human collagen ii
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
KR20140021589A (en) 2011-04-07 2014-02-20 제넨테크, 인크. Anti-fgfr4 antibodies and methods of use
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
CN102219860B (en) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc fusion protein and applications thereof
EP2723391B1 (en) * 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
KR102077721B1 (en) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions, Uses and Methods for Treatment of Metabolic Disorders and Diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
ES2915851T3 (en) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc FGF19 chimeric peptides for use in the treatment of bile acid disorders
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014105849A1 (en) * 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
JP2016520516A (en) * 2013-03-12 2016-07-14 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート Hybridoma clones and monoclonal antibodies against fibroblast growth factor 4
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
PE20160546A1 (en) 2013-10-25 2016-05-26 Novartis Ag BICYCLE PYRIDYL DERIVED COMPOUNDS FUSED TO RING AS INHIBITORS OF FGFR4
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
TW201612518A (en) * 2014-01-17 2016-04-01 Sanofi Sa Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
PT3170005T (en) 2014-07-18 2019-07-16 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN104177492B (en) * 2014-07-21 2017-02-22 暨南大学 FGFR2c extracellular domain analog, and coding gene and application thereof
PL3180356T3 (en) * 2014-08-11 2020-04-30 Daiichi Sankyo Europe Gmbh Human anti-fgfr4 antibody
JP6585167B2 (en) 2014-10-03 2019-10-02 ノバルティス アーゲー Use of fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
MX2017012295A (en) 2015-03-25 2018-01-09 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors.
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN108602890A (en) 2015-12-11 2018-09-28 瑞泽恩制药公司 Method for reducing or preventing the tumour growth resistant to EGFR and/or ERBB3 retarding agents
WO2017137503A1 (en) 2016-02-10 2017-08-17 Daiichi Sankyo Europe Gmbh Combination of human anti-fgfr4 antibody and sorafenib
EP3423089A4 (en) * 2016-03-04 2019-10-23 JN Biosciences, LLC Antibodies to tigit
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
JP7394623B2 (en) 2016-11-02 2023-12-08 ノバルティス アーゲー Combination of FGFR4 inhibitor and bile acid sequestrant
CA3043147A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
EP3444275A1 (en) * 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN109725159B (en) * 2018-12-28 2021-10-08 江苏众红生物工程创药研究院有限公司 Human beta2Quantitative detection test paper card of microglobulin and clinical application
EP4093430A4 (en) * 2020-01-21 2024-01-24 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
CR20220611A (en) 2020-06-02 2023-06-07 Arcus Biosciences Inc Antibodies to tigit
WO2022098662A2 (en) * 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants
CN118108840A (en) * 2022-11-29 2024-05-31 中国科学院深圳先进技术研究院 Anti-FGFR 4 monoclonal antibody, chimeric antigen receptor T cell targeting FGFR4 and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE60031793T2 (en) * 1999-12-29 2007-08-23 Immunogen Inc., Cambridge DOXORUBICIN AND DAUNORUBICIN-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE
EP2060270A3 (en) * 2003-10-16 2009-12-09 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
AU2007254005B2 (en) * 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
EP2433966A1 (en) * 2006-11-03 2012-03-28 U3 Pharma GmbH FGFR4 antibodies
CA2679268A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Treatment of melanoma

Also Published As

Publication number Publication date
AR072699A1 (en) 2010-09-15
CO6440535A2 (en) 2012-05-15
AU2009267834A1 (en) 2010-01-14
EA201170155A1 (en) 2011-08-30
TW201006492A (en) 2010-02-16
NZ590860A (en) 2012-12-21
EA021580B1 (en) 2015-07-30
AU2009267834B2 (en) 2014-10-23
EP2315781A2 (en) 2011-05-04
FR2933702A1 (en) 2010-01-15
WO2010004204A2 (en) 2010-01-14
WO2010004204A3 (en) 2010-04-29
ZA201100209B (en) 2012-04-25
JP2011527322A (en) 2011-10-27
MA32547B1 (en) 2011-08-01
HRP20150836T1 (en) 2015-09-11
CN102149730A (en) 2011-08-10
HK1159133A1 (en) 2012-07-27
UY31970A (en) 2010-02-26
SI2315781T1 (en) 2015-09-30
PT2315781E (en) 2015-09-21
DOP2011000005A (en) 2011-02-15
MX2011000328A (en) 2011-04-05
NZ602905A (en) 2014-05-30
ES2544761T3 (en) 2015-09-03
CR11868A (en) 2011-02-16
JP2015057398A (en) 2015-03-26
BRPI0915660A2 (en) 2019-08-27
ECSP11010748A (en) 2011-02-28
EP2315781B1 (en) 2015-05-06
CY1116847T1 (en) 2017-03-15
US20110150903A1 (en) 2011-06-23
DK2315781T3 (en) 2015-08-10
CL2011000047A1 (en) 2011-07-08
UA107782C2 (en) 2015-02-25
NI201100012A (en) 2011-07-20
JP5726731B2 (en) 2015-06-03
HN2011000074A (en) 2013-01-28
PE20110313A1 (en) 2011-06-21
PL2315781T3 (en) 2015-10-30
CN102149730B (en) 2014-03-26
KR20110028536A (en) 2011-03-18
CN103784954A (en) 2014-05-14
HUE027221T2 (en) 2016-10-28
IL210516A0 (en) 2011-03-31
CA2730300A1 (en) 2010-01-14
EA201401107A1 (en) 2015-05-29

Similar Documents

Publication Publication Date Title
HK1159133A1 (en) Fgf-r4 receptor-specific antagonists fgf-r4
IL219390A0 (en) Il-17a antagonists
HK1164639A1 (en) C5ar antagonists c5ar
IL195909A0 (en) Pan-cell surface receptor-specific therapeutics
HK1143994A1 (en) Glucagon antagonists
HK1203481A1 (en) Glucagon antagonists
EP2312947A4 (en) Trpv4 antagonists
IL201165A0 (en) CRIg ANTAGONISTS
EP2277678A4 (en) Exterior component
EP2478011A4 (en) Fluorinated ghrh antagonists
HK1149205A1 (en) Methods for inhibiting angiogenesis using egfl8 antagonists
ZA201008177B (en) Substituted quinazolines
EP2365748A4 (en) Imidazoisoindole neuropeptide s receptor antagonists
GB0808944D0 (en) Substituted quinazolines
GB0808947D0 (en) Substituted quinazolines
GB0808967D0 (en) Substitute quinazolines
GB0808950D0 (en) Substituted quinazolines
GB0808951D0 (en) Substituted quinazolines
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
GB0810005D0 (en) Substituted quinazolines
GB0808952D0 (en) Substituted quinazolines
GB0808953D0 (en) substituted quinazolines
GB0808968D0 (en) Substitute quinazolines
GB2457363B (en) Demarcation apparatus
GB0701632D0 (en) MET receptor antagonists